Keywords: Astellas, Drais Pharma, Telsar Pharma, ASP3291, Ulcerative colitis
Astellas partners with Drais to develop its ulcerative colitis compound
Article | 01 May 2012
Japanese drug major Astellas Pharma (TYO: 4503) has entered into a uniquely structured partnership with privately-held USA-based drug developer Drais Pharmaceuticals ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
